Ferring B.V. v. Watson Laboratories, Inc., No. 14-1377 (Fed. Cir. Aug. 22, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Ferring Corporation (“Ferring”), the owner of U.S. P a- tent Nos. 7,947,739 (“the ’739 patent”), 8,022,106 (“the ’106 patent”), and 8,273,795 (“the ’795 patent”) (collectiv e- ly, the “patents -in-suit”), alleges that Apotex Corporation (“Apotex”) infringed each and every claim of the patents - in-suit by filing an A bbreviated New Drug Application (“ANDA”). The United States District Court for the District of Nevada dismiss ed Ferring’s claims as moot in light of Apotex’s amendment to its ANDA which rendered the ANDA non-infringing. We affirm.